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Abstract
The Ras-related guanosine triphosphatase RhoA mediates pathological cardiac hypertrophy, but 
also promotes cell survival and is cardioprotective after ischemia/reperfusion injury. To 
understand how RhoA mediates these opposing roles in the myocardium, we generated mice with 
a cardiomyocyte-specific deletion of RhoA. Under normal conditions, the hearts from these mice 
showed functional, structural, and growth parameters similar to control mice. Additionally, the 
hearts of the cardiomyocyte-specific, RhoA-deficient mice subjected to transverse aortic 
constriction (TAC)--a procedure that induces pressure overload and, if prolonged, heart failure--
exhibited a similar amount of hypertrophy as wild-type mice subjected to TAC. Thus, neither 
normal cardiac homeostasis nor the initiation of compensatory hypertrophy required RhoA in 
cardiomyocytes. However, in response to chronic TAC, hearts from mice with cardiomyocyte-
specific deletion of RhoA showed greater dilation, with thinner ventricular walls and larger 
chamber dimensions, and more impaired contractile function than hearts from control mice 
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subjected to chronic TAC. These effects were associated with aberrant calcium signaling, as well 
as decreased activity of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and AKT. In 
addition, hearts from mice with cardiomyocyte-specific RhoA deficiency also showed less fibrosis 
in response to chronic TAC, with decreased transcriptional activation of genes involved in 
fibrosis, including myocardin response transcription factor (MRTF) and serum response factor 
(SRF), suggesting that the fibrotic response to stress in the heart depends on cardiomyocyte-
specific RhoA signaling. Our data indicated that RhoA regulates multiple pathways in 
cardiomyocytes, mediating both cardio-protective (hypertrophy without dilation) and cardio-
deleterious effects (fibrosis).
Introduction
Cardiomyocytes undergo remodeling in response to pathological stimuli, such as 
neurohumoral factors, pressure or volume overload, biomechanical stress, myocarditis, or 
inherited mutations (1–3). This causes cells to change morphology, increase protein 
synthesis and reactivate the cardiac fetal gene expression program. While initially 
compensatory, these changes ultimately prove maladaptive, leading to adverse ventricular 
remodeling through increased biomechanical stress, loss of contractility and function, and 
initiation of aberrant signaling processes that eventually cause heart failure. (1, 3). Thus, 
understanding the cellular signaling events regulating cardiac function may facilitate 
therapeutic measures to prevent development of cardiac disease.
RhoA belongs to the Rho subfamily of GTP-binding proteins that regulate the actin 
cytoskeleton. Specifically, RhoA plays a key role in both actin stress fiber formation and 
focal adhesion complex assembly in fibroblasts (4). Regulation of RhoA occurs at the levels 
of translocation from cytoplasm to the plasma membrane and GDP/GTP cycling (4, 5). The 
activation and inactivation of Rho-GTPase is thereby modulated by integrated internal 
signaling and/or extracellular signaling from G-protein coupled receptors (GPCRs), 
integrins and growth factor receptors (4, 6).
Once activated, RhoA signals directly to its two downstream effectors, the Rho kinases 
ROCK-1 and ROCK-2 (Rho-associated coiled-coil protein kinases). In smooth muscle, 
ROCK-1 phosphorylates the myosin binding subunit of myosin light chain (MLC) 
phosphatase, resulting in increased myosin phosphorylation and contraction, whereas 
ROCK-2 activates the LIM domain-containing kinase (LIMK), resulting in actin 
reorganization through inhibition of the globular G-actin state and depolymerization of 
filamentous F-actin, to facilitate cellular movement and contraction (7). Principally though, 
the role for RhoA signaling in smooth muscle is to mediate calcium sensitization and to 
enhance and sustain contraction, likely through downstream-mediated activation of 
transcriptional genes, such as the serum response factor (SRF).
In the myocardium, however, the role for RhoA is less defined and apparently dichotomous. 
Several studies, including investigations in humans, show important pathophysiological 
roles for RhoA in the cardiovascular system and in disease states such as hypertension, heart 
failure, stroke, and diabetes (8, 9). In mouse models, aberrant RhoA signaling is associated 
with in vivo pathological hypertrophy (4, 6, 10–14), apoptosis (15) and cardiomyopathy 
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(16). However, RhoA signaling also promotes cell survival through the regulation of 
phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK), AKT, and phosphatase and 
tensin homologue (PTEN) (15, 17). Indeed, and as testament to the bi-functional role for 
RhoA signaling in the heart, chronic administration of the ROCK inhibitors Y-27632 and 
fasudil prevents cardiac hypertrophy and remodeling (18, 19); however, pharmacological 
inhibition of ROCK-1 inhibits myocardial fibrosis, not hypertrophy, in response to 
myocardial infarction and chronic hypertension in a rat model of congestive heart failure 
(20, 21). In vivo, overt overexpression of RhoA leads to dilated cardiomyopathy and heart 
failure, inducing sinus and atrioventricular nodal dysfunction, severe edema, increased 
cardiac fibrosis, atrial enlargement, and decreased fractional shortening (13). However, 
conditional transgenic expression of low amounts of activated RhoA in cardiomyocytes 
confers protection against ischemia/reperfusion injury in vivo and in isolated perfused hearts 
(22). In addition, treatment of mice with the ROCK inhibitor Y-27632 reduces infarct size 
and apoptosis following ischemia/reperfusion ( 23, 24), yet mice deficient in RhoA show 
increased injury (22). Together, these data delineate different roles for RhoA in the heart; 
however, the mechanisms by which RhoA regulates cardiac contraction, fibrosis and 
hypertrophy have not yet been delineated, although similar mechanisms as those observed in 
smooth muscle cells have been proposed (25).
To directly determine the effects of RhoA specifically in cardiomyocytes and in response to 
chronic cardiac stress, we generated RhoAfl/fl mice crossed to mice expressing the Cre 
recombinase under the control of the α myosin heavy chain promoter (α MHC-Cre mice). 
Our data demonstrate that under these conditions, loss of RhoA in cardiomyocytes leads to 
decreased contractility, more severe heart failure, and decreased fibrosis, suggesting that 
RhoA is an integral and nodal enzyme necessary for cardiac function in response to stress in 
the heart.
Results
Mice with cardiomyocyte-specific deletion of RhoA do not have an overt basal 
pathological phenotype
We generated a “floxed” allele of RhoA (RhoAfl/fl) by flanking exon 3 with loxP sites and a 
Neomycin (Neo) cassette, which was flanked with frt sites. The Neo cassette was removed 
by crossing mice with flippase-mediated recombination (Frt mice), generating RhoAfl/fl 
mice that were then crossed to Cre recombinase for tissue specific deletion of RhoA 
(Supplemental Figure 1A). RhoAfl/fl mice were first crossed to Cre recombinase under the 
control of the Esr promoter to generate RhoAfl/fl-EsrCre mice, which harbor a ubiquitously 
expressing, tamoxifen (4HT) inducible promoter, to assess specificity for the deletion of 
RhoA. We generated multiple cell clones from mouse embryonic fibroblasts (MEFs) 
isolated from either RhoAfl/fl alone or the RhoAfl/fl-EsrCre mice. Cells were either left 
untreated or were treated with tamoxifen to determine effective deletion of RhoA 
(Supplemental Figure 1B); tamoxifen-treated RhoAfl/fl-EsrCre cells had less RhoA than 
untreated or treated RhoAfl/fl clones. The abundance of other GTPases and Rho family 
members was normal, indicating that there was specific deletion of RhoA and no 
compensation by other Rho family members (Supplemental Figure 1B). To assess the role of 
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RhoA in myocardium specifically, we next crossed the RhoAfl/fl mice to mice expressing 
Cre recombinase under the control of the α-myosin heavy chain (αMHC) promoter 
(Supplemental Figure 1C). As expected, hearts isolated from RhoAfl/fl-αMHC-Cre 
(hereafter (RhoAfl/fl-Cre) mice showed greater than 90% deletion of RhoA. The protein 
abundance of RhoA was normal in non-cardiac tissues, such as skeletal muscle, and there 
was no effect of deletion of RhoA in the total abundance of downstream effectors, such as 
AKT (Supplemental Figure 1C), suggesting specific cardiomyocyte-deletion of RhoA in 
these mice. The residual RhoA protein in hearts likely reflects RhoA in other resident 
cardiac cell types (for example, fibroblasts, vascular endothelial cells, and inflammatory 
cells).
RhoAfl/fl-Cre mice were born at the expected Mendelian ratio and did not have an overt 
phenotype. Cardiac structure and size were similar in 8-week old RhoAfl/fl-Cre and 
RhoA+/+-αMHC-Cre (control) mice (Supplemental Figure 2A). Histological analyses 
revealed no overt pathology, hypertrophy, or fibrosis in hearts from both lines, as assessed 
by hematoxylin and eosin (H&E) and Masson’s trichrome staining (Supplemental Figure 
2B). To determine whether loss of RhoA in cardiomyocytes affects cardiac function, we 
measured left ventricular posterior wall dimension (LVPWd), chamber dimension (LVDd) 
and fractional shortening (FS%) by echocardiography and found no significant differences 
between RhoAfl/fl-Cre and control mice (Supplemental Figure 2C). Thus, cardiomyocyte-
specific deletion of RhoA in adult mice is not sufficient to induce hypertrophy nor is it 
inherently pathological in the absence of stress.
Cardiomyocyte-specific deletion of RhoA leads to an accelerated dilated cardiomyopathy 
following chronic pressure overload
Cardiac overexpression (~20 fold higher) of RhoA leads to dilation and heart failure (13). 
However, in vivo overexpression to a lesser extent (~2 fold higher) of a constitutively active 
mutant of RhoA is cardioprotective, at least in response to acute ischemia/reperfusion injury 
(22). To assess the role of RhoA under chronic stress conditions, we subjected control and 
RhoAfl/fl-Cre mice to either 2 or 8-weeks of TAC (Figure 1). Although both control and 
RhoAfl/fl-Cre mice developed the expected compensatory cardiac hypertrophic responses 2-
weeks after TAC, we found that RhoAfl/fl-Cre mice subjected to 8-weeks of TAC had hearts 
that were grossly enlarged, with a dilated ventricular chamber, increased heart to body 
weight ratios, and a tendency to increased lung to body weight ratios, as compared to control 
mice (Figure 1A, 1B). These mice also had severe cellular pathology, including increased 
myofiber disarray, enlarged nuclei and increased interstitial space (Supplemental Figure 3). 
Together, these data suggest that RhoA in cardiomyocytes may be required to sustain 
compensatory hypertrophy by preventing the transition to dilation in response to chronic 
stress.
Cardiac-specific deletion of RhoA mice increases the severity of heart failure in response 
to chronic pressure overload
To confirm the phenotype observed by histology, we performed echocardiography to assess 
the cardiac function of both control and RhoAfl/fl-Cre mice in response to TAC (Figure 1C). 
After 8 weeks of TAC, left ventricular chamber diameter (LVDd) was significantly 
Lauriol et al. Page 4
Sci Signal. Author manuscript; available in PMC 2015 April 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
increased and left ventricular posterior wall thickness (LVPWd) was decreased, suggestive 
of a dilated cardiomyopathy (Figure 1D). Concomitant with these anatomic abnormalities, 
left ventricular function, as assessed by fractional shortening, was more impaired in 
RhoAfl/fl-Cre mice than in control mice (Figure 1D), suggesting an accelerated transition to 
heart failure. To validate these findings, we measured the haemodynamic parameters of 
these mice (Figure 1E). While hearts from control mice showed increased left ventricular 
pressure (LVP) in response to both 2- and 8- weeks of TAC, indicative of compensatory 
hypertrophy, the hearts from RhoAfl/fl-Cre mice developed increases in both left ventricular 
pressure and left ventricular volume, suggesting loss of contractility of the heart in these 
mice and greater cardiac dilation (Figure 1E). In addition, ventricular contractility (dP/dT) 
minimum and maximum were lower in cardiomyocyte-specific deleted RhoA hearts than in 
control hearts (Figure 1F), suggesting RhoAfl/fl-Cre mice were indeed transitioning to heart 
failure.
Reactivation of the fetal gene program is a hallmark feature of hypertrophied and failing 
hearts and correlates with impaired cardiac function and poor prognosis (26). To assess the 
effects of chronic stress on cardiac disease state, we measured the fetal gene expression 
profiles in control and cardiomyocyte-specific deleted RhoA mouse hearts at baseline and in 
response to 2- or 8-weeks of TAC. Both control and RhoAfl/fl-Cre hearts showed increased 
abundance of transcripts encoding atrial natriuretic factor (ANF) and brain natriuretic 
peptide (BNP). Moreover, in response to TAC, we observed a shift in mRNA expression 
from the adult αMHC to the fetal βMHC isoform in both controls and RhoAfl/fl-Cre hearts, 
indicating the onset of pathological hypertrophy. The decrease in αMHC expression after 8 
weeks of TAC was greater in RhoAfl/fl-Cre hearts than in control hearts (Figure 1G). Taken 
together, these data suggest that loss of RhoA in cardiomyocytes can be deleterious to the 
heart. Indeed, our data suggest that RhoA in cardiomyocytes is required to prolong the 
transition from hypertrophy to dilation and heart failure in response to chronic stress.
Cardiac-specific deletion of RhoA is associated with decreased contractility through 
modulation of calcium handling and myosin light chain activation
In response to pressure overload, we showed that loss of RhoA in cardiomyocytes leads to 
decreased contractility and accelerated dilated cardiomyopathy. Therefore, we next set out to 
analyze the downstream signaling pathways affected by RhoA loss in myocardium. In B 
cells, RhoA is important for BCR-dependent phosphatidylinositol (4,5) bisphosphate (PIP2) 
synthesis, phospholipase C (PLC) activation, calcium mobilization, and cell proliferation 
(27). Moreover, RhoA-activated ROCK promotes the intracellular localization and 
activation of the protein and lipid phosphatase PTEN, allowing it to convert 
phosphatidylinositol (3,4,5) triphosphate (PIP3) to PIP2 in leukocytes and human embryonic 
kidney cells (17). PIP2 is cleaved by PLC to generate inositol triphosphate (IP3) and 
diacylglycerol (DAG), two second messengers that mediate intracellular calcium release and 
hypertrophy and proliferation, respectively(28). To determine whether RhoA regulates 
similar signaling pathways in cardiomyocytes, we measured the abundance and 
phosphorylation of these enzymes. In response to TAC and when normalized against 
GAPDH, the total abundance and phosphorylation of PTEN were significantly increased in 
hearts from control mice (Fig. 2A). In contrast, PTEN abundance and phosphorylation were 
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basally higher, but decreased in response to TAC in hearts from RhoAfl/fl-Cre mice (Figure 
2A). PTEN phosphorylation was similar between mice subjected to sham operation or TAC, 
regardless of genotype (Fig. 2A). Phosphorylation-dependent activation of PLCβ (29) was 
also basally higher and decreased in response to TAC in hearts from RhoAfl/fl-Cre mice, as 
compared to hearts from control mice (Figure 2A). Together, these data suggest that RhoA 
signaling regulates PTEN and PLCβ activity in myocardium.
To directly assess whether loss of RhoA is associated with altered calcium release in 
cardiomyocytes, we measured the abundance of mRNA encoding the sarco(endo)plasmic 
reticulum calcium pump (SERCA) in response to TAC (Figure 2B). We found that SERCA 
mRNA abundance was decreased to a greater extent in hearts from RhoAfl/fl-Cre mice than 
in those from control mice (Figure 2C), suggesting a greater decrease in cardiac function and 
contractility (30). Next, we measured effects on calcium transient in individual 
cardiomyocytes left unstimulated or stimulated with endothelin-1 (ET-1), a neurohumoral 
agonist that mimics chronic stress in the heart (31). Basal and stimulated calcium transients 
were significantly lower in RhoAfl/fl-Cre cardiomyocytes than in control cells (Figure 2C), 
suggesting that RhoA might be involved in mediating increased calcium cycling in response 
to cardiac stress. Aberrant calcium handling in the heart leads to contractile dysfunction, 
arrhythmias, and heart failure (32). To determine whether suppressed calcium transients 
affect cardiac function and contractility, we measured phosphorylation of myosin light chain 
(MLC), an enzyme whose activity is necessary for muscle contraction (33) and that is a 
target of ROCK in smooth muscle cells (34, 35). When normalized to GAPDH, MLC 
phosphorylation was significantly diminished both basally and in response to TAC in 
RhoAfl/fl-Cre hearts, raising the possibility that decreased contractility in cardiomyocyte-
deleted RhoA mice is mediated by decreased MLC activity (Figure 2D).
Loss of RhoA in cardiomyocytes is associated with increased dilation and aberrant ERK 
and AKT activities
In addition to effects on contractility through IP3, cleavage of PIP2 into DAG may directly 
affect the compensatory hypertrophic signaling response. Activation of DAG leads to 
phosphorylation and activation of protein kinase C (PKC), which induces hypertrophy 
through indirect actions on the downstream effectors ERK1/2 and AKT (36, 37). To 
determine whether loss of RhoA affects PKC activity, we measured phosphorylation-
induced activation of PKC (38). The phosphorylation of PKC was basally lower and 
decreased in RhoAfl/fl-Cre hearts in response to TAC than in control hearts (Figure 2E). 
Further, phosphorylation of ERK1/2 and AKT, indicating activation of these kinases (39, 
40) were also lower in response to TAC in RhoAfl/fl-Cre hearts as compared to control, 
suggesting that both pro-hypertrophic (41) and pro-survival signals (42), respectively, are 
decreased in RhoAfl/fl-Cre hearts in response to TAC (Figure 2E). Note that basal activation 
of AKT was lower in RhoAfl/fl-Cre hearts. RhoA also mediates the activation of FAK (6, 43, 
44), and its activation in cardiomyocytes induces the activation of AKT in response to stress 
(15). To determine whether RhoA may be involved in FAK-mediated activation of AKT, we 
measured FAK phosphorylation in control or RhoAfl/fl-Cre hearts in response to TAC. In the 
absence of RhoA, the phosphorylation of FAK in response to TAC decreased significantly 
(Figure 2E), suggesting that this may be a possible mechanism for the decreased AKT 
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activity in these mice. Collectively, these data suggest that loss of RhoA in the myocardium 
may function to decrease signaling pathways that control cardiac function, thereby causing 
greater dilation, decreased contractility, and loss of hypertrophic response signals.
RhoA in cardiomyocytes is required for the fibrotic response to pressure overload in the 
heart
Pathophysiological cardiac hypertrophy and remodeling is usually accompanied by reactive 
fibrosis. However, although RhoAfl/fl-Cre mice showed severe dilated cardiomyopathy, the 
hearts from these mice had less fibrosis than those from control mice, even after 8 weeks of 
TAC (Figure 3A, 3B). Moreover, mRNA expression profiles for cardiac pro-fibrotic genes 
were also decreased in response to TAC in RhoAfl/fl-Cre hearts, as compared to controls 
(Supplemental Figure 4), further suggesting that RhoA signaling potentiates fibrosis in 
response to cardiac stress. These data also suggest that the signals needed to induce fibrosis 
are initiated specifically by RhoA signaling in cardiomyocytes. Because RhoAfl/fl-Cre hearts 
were dilated but showed reduced cardiac fibrosis following 8 weeks of TAC, we next 
assessed whether the effects observed were because of reduced myocyte apoptosis. Indeed, 
cardiomyocyte apoptosis was significantly reduced in RhoAfl/fl-Cre hearts as compared to 
controls, suggesting that loss of RhoA prevents induction of cardiac cell death in response to 
TAC (Figure 3C).
To delineate the biochemical mechanism associated with the decreased fibrosis in RhoAfl/fl-
Cre hearts, we measured the phosphorylation of two downstream effectors of ROCK, LIM 
domain kinase (LIMK) and the mitogen-activated protein kinase (MAPK) p38. RhoA/
ROCK activate LIMK, inducing the conversion of G-actin to F-actin (45). Under baseline 
conditions, G-actin is associated with myocardial response transcription factors (MRTFs), 
preventing them from entering the nucleus (46, 47). Mechanical or neurohumoral 
stimulation induces the polymerization of G-actin into F-actin, reducing the association of 
MRTFs with G-actin and promoting their nuclear translocation (48), thereby enabling the 
association of MRTF with SRF to induce transcriptional activation of genes that modulate 
contractility and induce fibrosis (49) (50). RhoA/ROCK also mediate activation of p38 (51), 
which leads to the phosphorylation and activation of SRF (52). Basal and TAC-induced 
activity of LIMK was significantly higher in control hearts than in RhoAfl/fl-Cre hearts. 
Moreover, though control hearts showed significantly increased p38 activity in response to 
TAC, p38 activity remained at baseline in the RhoAfl/fl-Cre hearts (Figure 3D). Finally, we 
observed an apparent (but not statistically significant) increase in F/G actin ratios following 
8 weeks of TAC in hearts from control mice, but not in RhoAfl/fl-Cre hearts (Figure 3E), 
suggesting that the loss of RhoA may prevent the conversion of G actin to F actin in 
response to TAC. In line with these data, RhoAfl/fl-Cre hearts also showed significantly 
reduced MRTF gene expression and a non-statistically significant decrease in SRF gene 
expression (Figure 3F).
Taken together, our data reveal that RhoA in cardiomyocytes prolongs compensatory 
hypertrophy, prevents transition to heart failure, and propagates the activation of fibrosis in 
response to chronic stress in the heart.
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Discussion
Our data demonstrate the necessity for RhoA signaling in the heart and suggest molecular 
mechanisms that mediate its function specifically in cardiomyocytes to control hypertrophy, 
contractility and fibrosis (Figure 4). We showed that cardiomyocyte-specific expression of 
RhoA was not required for normal homeostasis or for the initial compensatory hypertrophic 
response to stress. However, in response to chronic TAC, loss of cardiomyocyte-specific 
expression of RhoA caused accelerated dilation of the heart, suggesting RhoA is cardio-
protective and required for compensatory hypertrophy regulation and heart failure 
prevention.
In contrast, other groups have reported that loss of RhoA signaling is actually cardio-
protective, with beneficial effects observed following 3-weeks of TAC-induced hypertrophy 
in mice treated with inhibitors or with global deletions of ROCK1 or ROCK2 (12, 53) or 
with a cardiomyocyte-specific deletion of ROCK2 (54). There are several possible 
explanations for these discrepancies. First, while we observed no significant improvement in 
hypertrophy in our cardiomyocyte-deleted RhoA mice following 2 weeks of TAC, 
improvements in cardiac hypertrophic parameters as visualized by echocardiography may be 
apparent after 3 weeks. However, and secondly, because other groups assessed hypertrophy 
following 3 weeks of TAC, the “protective” effects may actually be the beginning of a 
transition to dilation. We showed that when pressure overload was extended to 8 weeks (to 
simulate chronic stress), loss of RhoA potentiated heart failure and accelerated dilation. 
Third, except for the mice with the cardiomyocyte-specific deletion of ROCK2 (54), which 
again only showed effects of TAC after 3 weeks, previous studies were conducted in vitro, 
in whole animal deletions of ROCK1/2, or by using ROCK inhibitors that may harbor off-
target effects and/or affect multiple cell types. Therefore, our model, in which RhoA was 
deleted specifically in cardiomyocytes, and in which an extended time course for pressure 
overload was examined, allowed for investigation of the specific role(s) of RhoA signaling 
in myocardium.
Calcium signaling is fundamental to cardiac contractility and hypertrophy. We showed that 
RhoA was involved in mediating increased calcium release in response to cardiac stress. The 
signaling mechanism(s) underlying RhoA-mediated calcium regulation in cardiomyocytes is 
complex and likely involves several pathways. For example, IP3 receptor abundance 
increases in response to pressure overload or neurohumoral stimulation, resulting in 
hypertrophic calcium signaling and concomitant pathological remodeling (55). In this 
regard, our data indicated that, in response to TAC, cardiomyocyte-specific expression of 
RhoA was required to stimulate IP3 and DAG signaling by maintaining basal PTEN 
abundance and increasing PLC activation, therefore suggesting RhoA may be required to 
mediate increased calcium signaling in the heart. In support of this hypothesis, muscle-
specific inactivation of Pten in mice confer beneficial effects in the heart in response to both 
pressure overload (56) and ischemia/reperfusion injury (57), further suggesting PTEN as a 
possible downstream effector of RhoA in calcium signaling.
RhoA may also play a key regulatory role in compensatory hypertrophy through ERK and 
AKT (36, 37). Our data indicated that RhoA in cardiomyocytes promoted the activation of 
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ERK in response to TAC, which could sustain and prolong the compensatory hypertrophic 
response to stress and prevent the transition to dilation and failure. In line with this, 
inhibition of RhoA/ROCK by Y-27632 suppresses phenylephrine-induced phosphorylation 
of ERK, which results in a decrease in the DNA binding activity of GATA-4, a zinc finger 
transcription factor necessary to induce cardiac hypertrophy (58). In vascular smooth muscle 
cells, RhoA-mediated actin cytoskeletal rearrangement is necessary for the translocation of 
ERK to the nucleus and induction of genes necessary for hypertrophy (59). In addition, 
platelet-derived growth factor (PDGF)-stimulated as well as stretch-induced ERK activation 
is diminished in smooth muscle cells in response to ROCK inhibition (60, 61).
Cardiac hypertrophy is accompanied by increased AKT activation (62), and RhoA can 
mediate the activation of AKT in cardiomyocytes through a pathway involving FAK and 
PI3K (15). However, RhoA has also been suggested to inhibit AKT signaling; for example, 
RhoA increases activity of PTEN in neutrophils and fibroblasts, but suppresses PI3K/AKT 
activities (17, 63). Similarly, AKT activation in endothelial cells and aortic tissue is 
increased when RhoA and/or ROCK are inhibited (24, 64). In contrast with these previous 
studies, but in line with our data, Del Re et al. suggest that RhoA mediates activation of 
AKT through FAK in cardiomyocytes in response to stress (15). In this regard, RhoA 
mediate the activation of FAK (6, 43, 44). Moreover, FAK associates with the regulatory 
p85 subunit of PI3K, activating it to mediate downstream activation of AKT, thereby 
implicating FAK in the activation of AKT (15) and in the development of cardiac 
hypertrophy and survival (65, 66).
We also showed a potential role for RhoA signaling in cardiomyocytes in the development 
of fibrosis. Hearts from RhoAfl/fl-Cre mice showed reduced reactive fibrosis following 
chronic pressure overload and reduced pathological induction of pro-fibrotic genes. Previous 
studies have shown that ROCK1 contributes to the development of cardiac fibrosis and 
induction of fibrogenic cytokines in response to pathological stimuli (12) and that 
haploinsufficiency of ROCK1 in mice reduces cardiac fibrosis without affecting Ang II–
induced hypertension and cardiac hypertrophy (67). However, these findings and our results 
directly contrast with previous studies showing that inhibition of ROCK1 and ROCK2 with 
Y27632 and fasudil prevent both myocyte hypertrophy and fibrosis in response to 
pathological stress in rats and mice (11, 20). Several explanations could account for these 
differences. First, ROCK inhibitors may not be entirely selective and could exert protecting 
effects by inhibiting other protein kinases, such as PKC and PKA, at higher concentrations. 
Secondly, our model only targets RhoA in cardiomyocytes; it is therefore possible that 
RhoA activity in other cardiac linend ages may be involved in initiating the hypertrophic 
signaling events that occur in response to stress. Finally, RhoA in cardiomyocytes may be 
critical for the maintenance, not initiation, of hypertrophy.
We showed that RhoAfl/fl-Cre mice had decreased transcriptional activation of genes 
involved in fibrosis, including MRTF and SRF, suggesting a RhoA-dependent myocardial 
signaling mechanism necessary to initiate the fibrotic response to stress in the heart. SRF is 
a ubiquitously distributed transcription factor critical for the control of morphogenetic 
movements and cell migration during embryonic development and for the regulation of 
cellular behavior in the adult (50). Induction of cardiomyocyte-specific deletion of SRF 
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leads to reduced expression of contractile genes and to death within 10 weeks as a result of 
cardiac dilation and heart failure (68). SRF is regulated by myocardin and MRTFs (MRTFa 
and MRTFb), cofactors that are necessary for the activation of genes encoding cardiac 
muscle and smooth muscle contractile proteins (69, 70). Indeed, scar formation and 
interstitial fibrosis in response to myocardial infarction or angiotensin II infusion, 
respectively, is decreased in MRTFa null mice (49). However, the fibrotic response to injury 
promotes infarct healing, as MRTFa null mice develop cardiac rupture (49). We suspect that 
MRTFs, like RhoA, may affect only the later, more chronic stages of cardiac remodeling.
RhoA regulates many aspects of MRTF and SRF activity and this study links reduced 
fibrosis to RhoA in cardiomyocytes through modulation of the MRTF–SRF signaling axis. 
Specifically, RhoA-mediated stimulation of ROCK leads to the activation of profilin and 
mDiaphanous and the incorporation of G-actin into growing F-actin (50). Simultaneously, 
activation of RhoA and ROCK leads to phosphorylation of LIMK, which inhibits cofilin-
mediated depolymerization of F-actin (71), further potentiating the nuclear accumulation of 
MRTFs and activation of SRF target genes. Lastly, MRTF activity is linked to TGF-β1, a 
proinflammatory cytokine that mediates the development of fibrosis, and mice expressing 
constitutively active ROCK develop fibrotic cardiomyopathy with diastolic dysfunction due 
to activated TGFβ1 and NF-κB (72).
In addition, our findings that cardiomycoyte-specific deletion of RhoA reduced cardiac 
fibrosis resembles other studies in which mice with cardiac-specific overexpression of 
dominant negative forms of p38α and p38β develop cardiac hypertrophy but not 
cardiomyocyte fibrosis in response to pressure overload (73). In addition, transgenic mice 
with cardiac-specific overexpression of the direct upstream activators of p38, MKK3bE or 
MKK6bE, develop cardiac fibrosis and systolic and diastolic dysfunction but not cardiac 
hypertrophy (74), further implicating p38 signaling in the development of fibrosis but not 
hypertrophy. Moreover, p38 inhibition improves cardiac function and attenuates cardiac 
remodeling following MI (75). Our data indicated that loss of RhoA in cardiomyocytes 
reduced p38 activity in response to TAC, suggesting an additional mechanism of regulating 
fibrosis. Indeed, p38 is a target of RhoA in non-cardiac cells (76) and in diabetic and failing 
mouse hearts (77, 78).
In conclusion, our data reveal that RhoA in cardiomyocytes can have both cardio-protective 
and cardio-deleterious: it prolongs compensatory hypertrophy and prevent transition to 
dilation and failure, but can also initiate the fibrotic response in a stressed heart.
Materials and Methods
Generation of RhoAF/F;αMHC-Cre mice
RhoA loxP-targeted (RhoAfl/fl) mice were generated by Dr. Chris Carpenter, in which exon 
3 was flanked by loxP sites to allow tissue-specific deletion (Supplemental Figure 1). These 
mice were then bred to C57/Bl6J mice expressing Cre recombinase under the control of the 
tamoxifen inducible estrogen receptor 1a (Esr) promoter (Jackson labs) or Cre recombinase 
under the control of the α-myosin heavy chain (αMHC) promoter (Dr. Dale Abel, 
University of Iowa) to generate cardiomyocyte-specific deletion of RhoA (RhoAfl/fl-αMHC-
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Cre). For all experiments herein, αMHC-Cre alone (RhoA+/+-αMHC-Cre) mice were used 
as controls.
Animal Procedures
All procedures were performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use Committee at 
BIDMC.
Histology
Hearts for morphometry and histochemistry were flushed with PBS, perfusion fixed in 
Bouin’s reagent, and paraffin embedded. Sections (5 μm) were stained with H&E, Masson-
Trichrome, or reticulin at the Rodent Histopathology Core (Dr. Roderick Bronson, Harvard 
Medical School). Cross sectional area of cardiomyocytes with centrally located nuclei (to 
ensure the same plane of sectioning) were measured using ImageJ 1.41 software (developed 
by Wayne Rasband; http://rsbweb.nih.gov/ij/). 200–500 cells were measured for each 
genotype. Masson’s trichrome stain, which stains collagen fibers blue, was used to quantify 
fibrosis. Images of the whole heart section were obtained and quantified on a Keyence 
BZ-9000 Microscope. Percentages of fibrotic area were obtained by dividing fibrosis area by 
the total ventricular area.
Quantitative real-time PCR
RNA was isolated from whole hearts with using the RNeasy Mini Kit (QIAGEN). 
Quantitative real-time PCR was performed with SYBR Green (Applied Biosystems), using 
an Applied Biosystems 7900. Gene expression analyses were carried out according to the 
manufacturer’s instructions. Primer sequences and conditions are listed in Supplemental 
Table 1. Each measurement was obtained using at least 3 mice per group, and each sample 
was measured in triplicate. Data were quantified by using the comparative CT method, with 
Gapdh and RPL13 expression as a control.
Echocardiography
Transthoracic echocardiography was conducted on non-anesthetized animals as described 
previously (79), with a 13-MHz probe (Vivid 7, GE Medical Systems, Boston, MA) or 
VisualSonics Vevo 770 high-frequency ultrasound rodent imaging system (VisualSonics). 
GE Medical Systems or VisualSonics Vevo 770 software was used for data acquisition and 
subsequent analysis. Hearts were imaged in the 2-dimensional parasternal short-axis view, 
and an M-mode echocardiogram of the midventricular region was recorded at the level of 
the papillary muscles. Calculations of cardiac anatomic and functional parameters were 
carried out as described previously (79).
Transverse aortic constriction and Hemodynamic studies
Transverse aortic banding was performed on anesthetized 16 week-old male mice (n=4–6 
mice per group at each time point). The ligature for aortic banding was sized by tying 
around a 25-gauge needle. The ligature was placed on the transverse aorta between the 
brachiocephalic trunk and the left common carotid artery. Sham-operated control mice 
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underwent the entire operative procedure without aortic banding. Cardiac function was 
evaluated by measuring the maximum rate of increase (dP/dtmax) and decline (dP/dtmin) in 
left ventricular pressure with a micromanometer catheter (Millar 1.4F, SPR 671, Millar 
Instruments) positioned in the left ventricle via a right common carotid artery cannulation.
Ca2+ Measurements in Adult Cardiomyocytes
Adult cardiomyocytes were isolated from αMHC-Cre or RhoAF/F-αMHC-Cre mice as 
previously described (80). Briefly, whole hearts were perfused with a Tyrode’s solution 
containing liberase blendzyme (Roche) at 37°C. Following cardiac perfusion, the ventricles 
were disassociated into individual myocytes, filtered and Ca2+ reintroduced and plated in 
laminin coated glass bottom dishes (MatTek). Myocytes were loaded with 2 μM Fura-2 AM 
(Invitrogen) and pluronic acid for 15 minutes in M199 media with 2,3-butanedione 
monoxime (Sigma) at room temperature. Cells were then washed and bathed in Ringer’s 
solution and electrically stimulated Ca2+ transients were acquired using a DeltaRam 
spectrofluorophotometer (Photon Technology International), operated at an emission 
wavelength of 510 nm, with excitation wavelengths of 340 and 380 nm. The myocytes were 
continuously paced at 0.5Hz for 60s in the presence of Ringer’s solution followed by 4 
minutes in the presence of Ringers solution with 100nM endothelin (Total perfusion time 
300s). Ca2+transients from 50–60s were averaged to obtain naive Ca2+ transient amplitude 
and Ca2+ transients from 290–300s were averaged to obtain endothelin stimulated Ca2+ 
transient amplitude. Percent change in the amplitude of Ca2+ transient was calculated by 
taking the difference between naïve and endothelin stimulated Ca2+ transient amplitude over 
naïve Ca2+ transient amplitude. Data were analyzed using Felix (Photon Technology 
International) and Clampfit (Molecular Devices) software.
Biochemical analyses
Whole hearts from αMHC-Cre or RhoAF/F-αMHC-Cre mice were dissected, perfused in 
PBS, and immediately frozen in liquid N2. Whole-cell lysates were prepared by 
homogenizing the tissue in radioimmunoprecipitation (RIPA) buffer (25 mmol/l Tris-HCl 
[pH 7.4], 150 mmol/l NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 5 mmol/l 
EDTA, 1 mmol/l NaF, 1 mmol/l sodium orthovanadate, and a protease cocktail) at 4°C, 
followed by clarification at 14,000 g. Proteins were resolved by SDS-PAGE and transferred 
to PVDF membranes. Immunoblots were performed, following the manufacturer’s 
directions, with anti-Akt (sc-8312), anti-phospho-FAK (sc-16563), anti-FAK (sc-558), anti-
LIMK (sc-5576), or pLIMK (sc-28409) antibodies (from Santa Cruz Biotechnology Inc.); or 
anti-phospho-Akt (9271), anti-phospho-Erk1/2 (9101), anti-Erk1/2 (9102), anti-phospho-
PTEN (9554), anti-phospho-PLCb, anti-phospho-MLC (3671), anti-PTEN (9188), anti-
phospho-PKC (9379), anti-PKC (2056), anti-phospho-p38 (4511), or anti-p38 (9212) 
antibodies (all from Cell Signaling Technology); or anti-PLCb (ABS512) antibodies (from 
Millipore). Bands were visualized with enhanced chemiluminescence and quantified by 
densitometry (ImageJ 1.41 software).
F/G actin ratio measurements
F-actin/G-actin ratios from control and RhoAfl/fl-Cre mouse hearts were assessed using 
animals that received sham operation or TAC for 8 weeks. Analysis of the F-Actin/G-actin 
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was generated using the In Vivo Assay Biochem Kit (Cytoskeleton Inc)and experiments 
were conducted according to the manufacturer instructions. Briefly, cells were lysed in a 
detergent based lysis buffer that stabilized and maintained the F and G forms of cellular 
actin. G actin was solubilized, whereas the insoluble F actin was pelleted by centrifugation. 
Samples of supernatant and pellet were visualized by SDS PAGE and the relative ratio of F 
to G actin was quantitated by western blot analysis using ImageJ. Samples from n=3 mice/
group were run in triplicates.
Statistics
All data are expressed as mean ± SEM. Statistical significance was determined using 2-
tailed Student’s t test and 1-way ANOVA or 2-way repeated measure ANOVA, as 
appropriate. If ANOVA was significant, individual differences were evaluated using the 
Bonferroni post-test. For all studies, values of p<0.05 were considered statistically 
significant. Statistical analysis was validated by Drs. Murray Mittleman and Erin Reese, 
through the support of Harvard Catalyst and The Harvard Clinical and Translational Science 
Center.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mice with cardiomyocyte-specific deletion of RhoA develop dilated cardiomyopathy, 
with decreased heart function and accelerated heart failure in response to chronic pressure 
overload
Control and RhoAfl/fl-Cre mice were subjected to either sham operation or TAC for 2 or 8 
weeks. (A) Representative longitudinal heart sections stained with H&E. Scale bar, 0.1mm. 
(B) Heart to body weight (HW/BW) and lung to body weight (LW/BW) ratios. (C) 
Representative echocardiographs and corresponding quantification of left ventricular end 
dimension in diastole (LVEDd), left ventricular posterior wall thickeness in diastole 
(LVPWd), and fractional shortening (FS). (D) Representative pressure-volume loops and 
corresponding hemodynamic assessment of contraction velocities (maximum and minimum 
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pressure difference over time [dP/dt]). (E) qRT-PCR analysis of hypertrophy-related gene 
expression, which was normalized to RPL13 mRNA. Results were normalized to sham-
operated mice of the same genotype. Samples were obtained from 3 mice per group and 
each sample was assessed in technical triplicate. n=4–6 mice/group for data in (A), (B), (C), 
(D), and n=3–4 mice/group for data in (E). Data in graphs represent mean ± SEM; *p<0.05, 
as compared to corresponding shams and #p<0.05. All p values were derived from ANOVA 
and Bonferroni post-test when ANOVA was significant.
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Figure 2. Cardiomyocyte-specific deletion of RhoA may affect contractility by modulating 
calcium handling and myosin light chain activation and accelerating dilation through aberrant 
Erk and Akt activities
(A) Whole heart lysates from control or RhoAfl/fl-Cre mice subjected to either sham or acute 
TAC for 10 minutes were immunoblotted for phosphorylated PTEN and PLCβ, with total 
PTEN, PLCβ, and GAPDH as loading controls. Each lane represents one animal. (B) 
SERCA2A mRNA expression as assessed by qRT-PCR (n=3–4 mice/group), which was 
normalized to RPL13 mRNA. Results were normalized to sham-operated mice of the same 
genotype. Each sample was assessed in triplicate. (C) Percent change in amplitude of Ca2+ 
transients and time constant of Ca2+ decay from the indicated genotypes in the absence or 
presence of endothelin. At least 3 animals were used for each genotype with a total of 20–25 
myocytes under each condition. (D) Whole heart lysates were immunoblotted for 
phosphorylated myosin light chain (pMLC), with total GAPDH used as the loading control. 
(E) Whole heart lysates were immunoblotted for phosphorylated PKC, Erk1/2, FAK, and 
AKT antibodies, with total PKC, Erk1/2, FAK, and AKT used as loading controls. In (D) 
and (E), n=3 animals per group, and each lane represents one animal. Data in graphs 
represent mean ± SEM; *p<0.05, compared to corresponding shams and #p<0.05. All p 
values were derived from ANOVA and Bonferroni post-test when ANOVA was significant.
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Figure 3. Cardiomyocyte-specific deletion of RhoA reduces cardiac fibrosis induced by pressure 
overload
(A) Perivascular and interstitial fibrosis in control and RhoAfl/fl-Cre mouse hearts following 
either sham operation or TAC for 2 or 8 weeks, as assessed by Masson-Trichrome staining 
of paraffin-embedded longitudinal sections. Scale bar, 100 μm. Images are respresentative of 
n=4 animals/group. (B) Quantification of fibrotic area from n=4 animals/group from control 
or RhoAfl/fl-Cre mouse hearts following either sham operation or TAC for 8 weeks. (C) 
Quantification of apoptotic cells (positive for TUNEL staining) from control or RhoAfl/fl-
Cre mouse hearts following either sham operation or TAC for 8 weeks. N=3 animals per 
treatment, with at least 5 sections quantified per heart. (D) Whole heart lysates from either 
control or RhoAfl/fl-Cre mice subjected to either sham or acute TAC for 10 minutes were 
immunoblotted for phosphorylated LIMK and p38 MAPK antibodies, with total LIMK, p38, 
and GAPDH as loading controls. Each lane represents one animal, where n=3 animals/group 
(E) F-Actin to G-Actin ratios of control and RhoAfl/fl-Cre mouse hearts following either 
sham operation or TAC for 8 weeks. Results were normalized to relative sham-operated 
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mice. n=3 mice/group. Each sample was assessed in triplicate. Data in graphs represent 
mean ± SEM. (F) MRTFa and SRF mRNA expression as assessed by qRT-PCR (n=3–4 
mice/group), which was normalized to RPL13 mRNA. Results were normalized to sham-
operated mice of the same genotype. Each sample was assessed in triplicate. Data in graphs 
represent mean ± SEM;*p<0.05. All p values were derived from ANOVA and Bonferroni 
post-test when ANOVA was significant.
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Figure 4. Model for the role of cardiomyocyte-specific expression of RhoA in pathological 
hypertrophy
RhoA sustains and enhances the compensatory hypertrophic signaling responses to stress in 
the heart. We propose that RhoA (i) increases contractility through increased calcium and 
MLC signaling, (ii) sustains hypertrophy through increased activities of both ERK1/2 and 
AKT, and (iii) initiates the fibrotic response through activation of LIMK, the MAPK p38, 
and induction of transcriptional regulators of fibrosis.
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